News Contact Us

Roche steps up cost cuts via efficiency to stay ahead of opponents

Author : Sunil Hebbalkar | Published Date : 2018-09-15 

Roche, the biggest manufacturer of cancer medications across the world, has reportedly started an efficiency drive in a bid to counterattack competition by employing cost cuts. According to sources familiar with the development, Roche is struggling with sales as its biotech product portfolio ages amid intensifying rivalries, though it owns the best research and development laboratories in the pharmaceutical industry.

Severin Schwan, the Chief Executive, was quoted stating that he believes that he would be able to seal the sales gap with an anticipated moderate growth in the year 2019, accredited to new drugs like Ocrevus that treats multiple sclerosis. Schwan added that with companies having a sharp portfolio shift like Roche, it is imperative to dramatically reallocate resources, and Roche is currently working on the same lines.

Schwan also claimed that though the company’s Tecentriq immunotherapy failed to combat Merck & Company’s Keytruda for treating first-line lung cancer there are still important opportunities, especially in the hard-to-treat breast cancer market.

Market experts claim that the company needs to make big moves to retain its market position. Roche estimates that it would have a giant $10 Bn sales gap to seal by 2022, from competitor invasions in the cancer treatment sector, a territory that the Swiss drugmaker has dominated till date, claim sources.

Reportedly, the three top-selling drugs by Roche are used in cancer treatment and had a joint sales of 21 billion dollars in 2017, which made up for 40 percent of its overall sales. 

Incidentally, in the European domain where biosimilars are majorly influencing the industry, the cost-cutting drive by Roche is an advanced step wherein few commercial operations are trimmed back.

According to sources familiar with the development, Roche intends to restrict its research & development activities and wants to stick by a long-standing business strategy of utilizing only small to mid-level bolt-on acquisitions to bolster its drug pipeline, instead of purchasing big drug business.

About Author

Sunil Hebbalkar

Sunil Hebbalkar

Sunil Hebbalkar currently works as a content writer for fractovia.org and other portals. A post graduate in mechanical design engineering, he nurtures a passion for writing articles related to myriad industry verticals such as the technology, automotive, and healthcare sectors. When free, Sunil pursues his interest in cycling, reading, and sketching. He can be contacted at- [email protected]g | https://twitter.com/HSuniel

Related News

Titanium sponge: An overview of the material in terms of physical properties, grades, and applications

Published Date: 2019-02-26         Author: Sunil Hebbalkar

In recent decades, the increasing involvement of the scientific community in the development of material science and technologies has led to the introduction of innovative material alternatives. These alternatives have apparently been gaining considerable popularity among prominent industries such a... Read More

Entergy to build 100 MW solar energy plant in Mississippi Delta

Published Date: 2018-11-10         Author: Sunil Hebbalkar

U.S. based energy company, Entergy Mississippi, Inc. has signed a deal with a Canadian energy company to construct solar energy farm of 100 MW capacity. This will be one of the largest utility-owned solar energy firms in the state. The Mississippi Public Service Commission hasn’t provided sanc... Read More

U.S. military to pour in USD 2 billion in next-gen AI projects

Published Date: 2018-09-10         Author: Sunil Hebbalkar

The Pentagon research wing has reportedly stated that it would be investing USD 2 billion to create the next generation of artificial intelligence devices that boast of ‘human-like communication’ ability. The new smart machines referred to as ‘AI Next’ would escalate military... Read More

© 2019 Fractovia. All Rights Reserved